Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity in the provided document. The company plans a capex of about INR540 crores for FY27. This entire capex will be funded through internal accruals, indicating no need for external financing. The cash position is strong, with cash and cash equivalents at INR782 crores as of March 31, 2026. There is confidence expressed in maintaining investment and growth without the need for external fundraising.

Any current/future capex/capital investment/strategic investment?

FY27 capex planned at about INR 540 crores, including carryover from FY26 and fresh investments. Entire capex funded through internal accruals. Investments focus on building new capabilities at Solapur (greenfield project) and strengthening the R&D platform. Capacity expansion to increase from 1,198 KL in FY24 to a planned 2,690 KL by FY28. Solapur facility: Phase 1 includes 370 KL for BI block and 120 KL for API block, with 40-50% initial utilization. Brownfield expansions at Ankleshwar and Dahej, with rapid ramp-up expected within 2-3 quarters. Solapur has land bank for additional 700-800 KL

Future growth expectations in sales/revenue/volumes?

Non-GPL business is already growing at double-digit; expected to continue outpacing GPL business. Overall sales volume growth across segments is significant and expected to persist. New product launches contribute to growth, though not yet a major revenue driver. Capacity expansions (Solapur greenfield, brownfield expansions at Ankleshwar and Dahej) will enable volume and revenue growth post ramp-up. Solapur Phase 1 expected to start with 40-50% utilization, scaling to 60-70% gradually. New launches and pipeline buildup (especially complex molecules and high-potent APIs) underpin medium- to lo

Future growth expectations in earnings/operating earnings/profits/EPS?

The company aims for sustained profitable growth by focusing on unique, high-entry-barrier products, fostering differentiation and sustainable margins. Non-GPL business is growing at double-digit rates, expected to continue, reducing dependency on GPL business. Gross margins improved to 58.2% in FY26 with a target to maintain EBITDA margins between 30%-32%. New capacity additions, especially from Solapur and brownfield expansions, will enable revenue growth from FY28 onwards. CDMO segment is gaining momentum, with new projects and contract deals expected in H2 FY27, contributing to future grow

Current/ Expected Orderbook/ Pending Orders?

Alivus Life Sciences operates primarily on long-term contracts in its CDMO business. In the generic API segment, contracts are fewer and typically short-term, lasting about 1-2 years. The company prefers short to medium-term contracts to maintain flexibility due to a dynamic environment. This flexibility helps them respond to market changes, such as price increases related to external factors (e.g., war situations). Orders are generally placed by customers as needed, without getting locked into cumbersome clauses. No specific figures on current or expected orderbook/pending orders were disclos

IN US

Sale is live|00:00:00left today

Alivus Life Sciences LtdQ1 FY26Pharmaceuticals & Biotechnology

Alivus Life Sciences Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,108P/E: 22.7Market Cap: ₹12.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

→Non-GPL business is already growing at double-digit; expected to continue outpacing GPL business.
→Overall sales volume growth across segments is significant and expected to persist.
→New product launches contribute to growth, though not yet a major revenue driver.
→Capacity expansions (Solapur greenfield, brownfield expansions at Ankleshwar and Dahej) will enable volume and revenue growth post ramp-up.
→Solapur Phase 1 expected to start with 40-50% utilization, scaling to 60-70% gradually.
→New launches and pipeline buildup (especially complex molecules and high-potent APIs) underpin medium- to long-term growth.
→CDMO business ramping up with new projects commencing, supporting future revenue momentum.
→Balanced geographic diversification (India, Europe, Latin America, US, Japan) aids steady growth.
→Focus remains on profitable, high-quality growth rather than volume at cost of margins.

Margin guidance

Category 3

→The company aims for sustained profitable growth by focusing on unique, high-entry-barrier products, fostering differentiation and sustainable margins.
→Non-GPL business is growing at double-digit rates, expected to continue, reducing dependency on GPL business.
→Gross margins improved to 58.2% in FY26 with a target to maintain EBITDA margins between 30%-32%.
→New capacity additions, especially from Solapur and brownfield expansions, will enable revenue growth from FY28 onwards.
→CDMO segment is gaining momentum, with new projects and contract deals expected in H2 FY27, contributing to future growth.
→R&D spend is set to stabilize around 4% of sales, driving innovation in flow chemistry, high-potent APIs, pellets, and granules.
→Price erosion in base non-GPL, non-CDMO business is approximately 5.5% but offset by volume growth.
→Overall revenue CAGR was 5.7% (FY24-FY26) with EBITDA CAGR at 15.8%; double-digit top-line growth targeted in non-GPL segments.
→Capex of INR540 crores planned for FY27, funded via internal accruals, supporting capacity and product pipeline expansion.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or planned fundraising through debt or equity in the provided document.
→The company plans a capex of about INR540 crores for FY27.
→This entire capex will be funded through internal accruals, indicating no need for external financing.
→The cash position is strong, with cash and cash equivalents at INR782 crores as of March 31, 2026.
→There is confidence expressed in maintaining investment and growth without the need for external fundraising.

Order book

→Alivus Life Sciences operates primarily on long-term contracts in its CDMO business.
→In the generic API segment, contracts are fewer and typically short-term, lasting about 1-2 years.
→The company prefers short to medium-term contracts to maintain flexibility due to a dynamic environment.
→This flexibility helps them respond to market changes, such as price increases related to external factors (e.g., war situations).
→Orders are generally placed by customers as needed, without getting locked into cumbersome clauses.
→No specific figures on current or expected orderbook/pending orders were disclosed in the transcript.

Capex plans

Yes

→FY27 capex planned at about INR 540 crores, including carryover from FY26 and fresh investments.
→Entire capex funded through internal accruals.
→Investments focus on building new capabilities at Solapur (greenfield project) and strengthening the R&D platform.
→Capacity expansion to increase from 1,198 KL in FY24 to a planned 2,690 KL by FY28.
→Solapur facility: Phase 1 includes 370 KL for BI block and 120 KL for API block, with 40-50% initial utilization.
→Brownfield expansions at Ankleshwar and Dahej, with rapid ramp-up expected within 2-3 quarters.
→Solapur has land bank for additional 700-800 KL capacity, offering runway for 3-4 years.
→R&D spend expected to rise to about 4% of sales over the next 1-2 years and then stabilize.
→Focus areas: flow chemistry, high potent APIs, pellets and granules, and lateral expansion of the API portfolio.

How does Alivus Life Sciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Alivus Life Sciences Ltd

Rev 4Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Alivus Life Sciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio